Drugs / Antigen-specific CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06739226 | Aug 2025 → Dec 2028 expected | melanoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antigen-specific CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739226 ↗ |
| Action | Deplete | “CAR T cells are a specialized type of T cells engineered to recognize and eliminate tumor cells by targeting specific surface antigens.” NCT06739226 ↗ |
| Modality | Cell therapy | “CAR T cell therapy” NCT06739226 ↗ |